Kronos Bio (Kronos Bio) Gross-Profit-to-Asset %

: 4.05% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kronos Bio's annualized Gross Profit for the quarter that ended in Dec. 2023 was $9.14 Mil. Kronos Bio's average Total Assets over the quarter that ended in Dec. 2023 was $225.64 Mil. Therefore, Kronos Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 4.05%.

Kronos Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Kronos Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

2.47

Kronos Bio Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %																-	1.67	2.71	1.47	4.05

Competitive Comparison

For the Biotechnology subindustry, Kronos Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kronos Bio Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, Kronos Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Gross-Profit-to-Asset % falls into.

Kronos Bio Gross-Profit-to-Asset % Calculation

Kronos Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	6.288	/	( (294.938	+	213.279)	/ 2 )
	=	6.288	/	254.1085
	=	2.47 %

Kronos Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	9.144	/	( (237.993	+	213.279)	/ 2 )
	=	9.144	/	225.636
	=	4.05 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Kronos Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kronos Bio (Kronos Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402

Website

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Executives

Jorge Dimartino	officer: Chief Medical Officer & VP	C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore	officer: Chief Scientific Officer	C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz	officer: COO & General Counsel	3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger	director, 10 percent owner, officer: President & CEO	333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner	officer: Interim CFO	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130